Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Other Non-Current Liabilities?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1996 - 2021 (26 years)

Other Non-Current Liabilities is 
$2.6B (1Y +14.7% )

ALXN Stock Price & Other Non-Current Liabilities

Other Non-Current Liabilities for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Other Non-Current Liabilities

chevron_right 2021 $598.2M 0
( 0 / year avg)
chevron_left 1996 0.0
vertical_align_top Peak $2.5B -
vertical_align_bottom Bottom 0.0
arrow_drop_up # Up Years 15 15 of 26
years up.
arrow_drop_down # Down Years 9
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1996 , or 0% the rate relative to it's other non-current liabilities over the same period.
  • If ALXN shrinks it's stock at the same rate as it's other non-current liabilities (0/year) , it's stock price will shrink 0 and hit $0 over the next 10 years.
  • ALXN's stock price has gone up 9 of the 15 years (+60%) it's other non-current liabilities were also up.
  • ALXN Historical Other Non-Current Liabilities Table
    in $ million
    Year Other Non-Current Liabilities YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $598 -75.9% $108.72 -9.3%
    4/1/2020 $2,479 49.6% $119.9 5.5%
    4/1/2019 $1,657 36.9% $113.68 -2.1%
    4/1/2018 $1,210 17.6% $116.13 18.5%
    4/1/2017 $1,029 59.9% $98.03 -30.4%
    4/1/2016 $643 -33.0% $140.8 -21.9%
    4/1/2015 $960 55.0% $180.37 2.0%
    4/1/2014 $619 -14.0% $176.8 91.9%
    4/1/2013 $720 105.4% $92.14 -0.8%
    4/1/2012 $350 793.4% $92.86 88.2%
    4/1/2011 $39 133.1% $49.34 81.5%
    4/1/2010 $16 -12.9% $27.18 44.4%
    4/1/2009 $19 544.1% $18.83 27.0%
    4/1/2008 $3 -76.5% $14.82 37.1%
    4/1/2007 $12 -72.3% $10.81 22.1%
    4/1/2006 $46 94.3% $8.86 63.5%
    4/1/2005 $23 -20.6% $5.42 -8.8%
    4/1/2004 $29 6.8% $5.94 80.8%
    4/1/2003 $27 -5.7% $3.29 -28.8%
    4/1/2002 $29 24.7% $4.62 -19.0%
    4/1/2001 $23 - $5.7 -73.2%
    4/1/2000 $0 -100.0% $21.31 633.3%
    4/1/1999 $0 0.0% $2.91 -13.1%
    4/1/1998 $0 - $3.34 48.6%
    4/1/1997 $0 - $2.25 -2.7%
    4/1/1996 $0 - $2.31 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Non-current liabilities include debentures, long-term loans, bonds payable, deferred tax liabilities, long-term lease obligations, and pension benefit obligations. The portion of a bond liability that will not be paid within the upcoming year is classified as a non-current liability.

    Other non-current liabilities are current liabilties that are not specified in the financial statement.

    For more detailed definitions, please see Investopedia.